麻豆传媒

Afinitor racks up FDA approvals, but where is the evidence?

Celebrities tout ease of new anticoagulants, but is there real benefit?

Trial data from more than 300 patients is missing

In another edition of the Slippery Slope series examining use of surrogate endpoints in drug approvals, 麻豆传媒 and the Milwaukee Journal Sentinel find diet drugs are approved without solid evidence of benefits, but with hints of harm.

Makers of diet drugs spent more than $60 million on payments to doctors, organized medicine, and lobbyists to get their drugs approved.

Fen-phen use was linked to heart valve damage, as these two cases illustrate.